{"id":"NCT00918346","sponsor":"Santen Oy","briefTitle":"Pharmacodynamics of Tafluprost 0.0015% Eye Drops: a Comparison Between the Preserved and Unpreserved Formulation","officialTitle":"Pharmacodynamics of Tafluprost 0.0015% Eye Drops: a Comparison Between the Preserved and Unpreserved Formulation in Patients With Open-angle Glaucoma or Ocular Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-09","primaryCompletion":"2006-03","completion":"2006-04","firstPosted":"2009-06-11","resultsPosted":"2009-09-15","lastUpdate":"2010-12-28"},"enrollment":43,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Open-Angle Glaucoma","Ocular Hypertension"],"interventions":[{"type":"DRUG","name":"Tafluprost 0.0015%","otherNames":[]}],"arms":[{"label":"Tafluprost 0.0015% preserved formulation","type":"EXPERIMENTAL"},{"label":"Tafluprost 0.0015% unpreserved formulation","type":"EXPERIMENTAL"}],"summary":"The objective of this study is to investigate the pharmacodynamics (as expressed in intraocular pressure \\[IOP\\]) of two formulations of tafluprost 0.0015% eyedrops (preserved and unpreserved) in patients with open-angle glaucoma or ocular hypertension.\n\nThe primary aim of this study is to show that IOP reduction between the two formulations is equivalent at the end of the 4 week treatment period.","primaryOutcome":{"measure":"Intraocular Pressures (IOPs) at Baseline","timeFrame":"Baseline","effectByArm":[{"arm":"Preserved Formulation","deltaMin":22.57,"sd":3.04},{"arm":"Unpreserved Formulation","deltaMin":22.98,"sd":3.18}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":3,"countries":["Finland","Germany"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":42},"commonTop":["Conjunctival hyperemia","Ocular hyperemia","Erythema of eyelid","Eye pruritus","Foreign body sensation"]}}